RBM17抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse liver tissue lysate, Primary antibody: P09702(RBM17 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P09702(RBM17 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The RBM17 (RNA Binding Motif Protein 17) antibody is a tool used to study the function and expression of the RBM17 protein, a member of the RNA-binding protein family. RBM17. also known as SPF45. plays a critical role in pre-mRNA splicing by interacting with spliceosome components like the SF3b complex. It contains an RNA recognition motif (RRM) that enables binding to specific RNA sequences, influencing splice site selection and alternative splicing events. Dysregulation of RBM17 has been implicated in cancer progression, particularly in tumors such as lung, colorectal, and ovarian cancers, where its overexpression correlates with aberrant splicing of oncogenic transcripts, enhanced cell proliferation, and metastasis.

Researchers employ RBM17 antibodies in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect protein levels, localization, and interactions in cellular and tissue samples. These studies help elucidate RBM17's role in splicing regulation, its association with splicing-related diseases, and its potential as a therapeutic target or biomarker. Notably, RBM17's involvement in DNA damage response pathways and its interaction with proteins like BRCA1 further highlight its multifaceted functions. However, challenges remain in understanding its precise regulatory mechanisms and tissue-specific roles, underscoring the importance of reliable antibodies for ongoing research.